Last reviewed · How we verify
Rivaroxaban granules for oral suspension — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Rivaroxaban granules for oral suspension (Rivaroxaban granules for oral suspension) — Bayer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rivaroxaban granules for oral suspension TARGET | Rivaroxaban granules for oral suspension | Bayer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rivaroxaban granules for oral suspension CI watch — RSS
- Rivaroxaban granules for oral suspension CI watch — Atom
- Rivaroxaban granules for oral suspension CI watch — JSON
- Rivaroxaban granules for oral suspension alone — RSS
Cite this brief
Drug Landscape (2026). Rivaroxaban granules for oral suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban-granules-for-oral-suspension. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab